Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -2.13% is 94% above its 3-year average of -34.50%, near the high end of its 3-year range (-165.44%–-2.13%).
As of the fiscal period ended Friday, July 31, 2026. 94.36% above its 12-month average of -37.76%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q3 FY2026 (2026-07-31): -2.13%.
RETURN ON EQUITY (ROE)
-2.13%
RETURN ON EQUITY (ROE) AVG TTM
-37.76%
RETURN ON EQUITY (ROE) AVG 3Y
-35.65%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+94.36%
CURRENT VS 3Y AVG
+94.03%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 654 covered companies
CURRENT VS SECTOR MEDIAN
+94.70%
vs the sector median at left
enGene Holdings Inc.
Market Cap
$122.26M
Return on Equity (ROE)
-2.13%
TTM Avg
-37.76%
3Y Avg
-35.65%
5Y Avg
N/A
Market Cap
$122.27M
Return on Equity (ROE)
-165.57%
TTM Avg
-146.09%
3Y Avg
30.63%
5Y Avg
465.14%
Market Cap
$122.13M
Return on Equity (ROE)
-663.38%
TTM Avg
-427.48%
3Y Avg
-294.92%
5Y Avg
-251.31%
Market Cap
$121.23M
Return on Equity (ROE)
-30.12%
TTM Avg
-27.41%
3Y Avg
-24.34%
5Y Avg
-19.85%
Market Cap
$125.34M
Return on Equity (ROE)
N/A
TTM Avg
143.89%
3Y Avg
2.05%
5Y Avg
-53.47%
Market Cap
$126.43M
Return on Equity (ROE)
-234.42%
TTM Avg
-102.69%
3Y Avg
-100.55%
5Y Avg
-100.92%
Market Cap
$118.05M
Return on Equity (ROE)
-57.47%
TTM Avg
-26.63%
3Y Avg
16.73%
5Y Avg
210.40%
Market Cap
$117.53M
Return on Equity (ROE)
-105.40%
TTM Avg
-90.09%
3Y Avg
-60.23%
5Y Avg
-18.64%
Market Cap
$116.82M
Return on Equity (ROE)
-0.05%
TTM Avg
-43.47%
3Y Avg
9.13%
5Y Avg
-18.50%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| enGene Holdings Inc. (ENGN) | $122.26M | -2.13% | -37.76% | -35.65% | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $122.27M | -165.57% | -146.09% | 30.63% | 465.14% |
| Cibus, Inc. (CBUS)vs › | $122.13M | -663.38% | -427.48% | -294.92% | -251.31% |
| Seer, Inc. (SEER)vs › | $121.23M | -30.12% | -27.41% | -24.34% | -19.85% |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $125.34M | N/A | 143.89% | 2.05% | -53.47% |
| Entera Bio Ltd. (ENTX)vs › | $126.43M | -234.42% | -102.69% | -100.55% | -100.92% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.05M | -57.47% | -26.63% | 16.73% | 210.40% |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.53M | -105.40% | -90.09% | -60.23% | -18.64% |
| Coya Therapeutics, Inc. (COYA)vs › | $116.82M | -0.05% | -43.47% | 9.13% | -18.50% |
| Genelux Corporation (GNLX)vs › | $116.14M | -209.73% | -196.07% | -130.72% | -67.26% |
ROE
-2.1%
ROA
-1.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-07-31 | -2.13% |
| 2026-04-30 | -26.02% |
| 2026-01-31 | -43.49% |
| 2025-10-31 | -69.94% |
| 2025-07-31 | -47.20% |
| 2025-04-30 | -35.14% |
| 2025-01-31 | -27.62% |
| 2024-10-31 | -20.23% |
| 2024-07-31 | -53.12% |
| 2024-04-30 | -46.47% |
| 2024-01-31 | -165.44% |
| 2023-10-31 | -137.84% |
| 2023-07-31 | -20.73% |
| 2023-04-30 | -21.89% |
